Study 19 of 29Semaglutide literatureBMJ (Clinical research ed.)Top journal2026
Artificial intelligence as a new commercial determinant of health.
Not reported in abstract.
Where it sits
this study against the rest of the semaglutide corpus7
Preclinical · this one
16
Observational
0
Open-label
2
Randomised
4
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.00). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Elsewhere in the Semaglutide corpus
DCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2026—DEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026—D1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.The lancet. Diabetes & endocrinology · 2026—BComparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · sleeve gastrectomy group had a BMI reduction difference of 4.04 kg/m² compared to the semaglutide group, p < 0.05HumanBGLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubesbiorxiv-preprint · 2026 · Semaglutide reduced glycolytic and total ATP production rates, exact values not reported.HumanBReal-World Study of Cardiac Remodeling on Semaglutide and Tirzepatide Therapy Using Longitudinal Echocardiographybiorxiv-preprint · 2026 · LV mass decreased from 198.4 ± 69.6 g to 176.6 ± 66.0 g in super-responders, p < 0.001.Human